MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- , the leading pioneer in clinical trial technology, today announced the launch of its groundbreaking glucometer functionality designed to integrate seamlessly with its eCOA platform. This functionality, developed in close collaboration with patients living with diabetes, will transform endocrinology and autoimmune clinical trials by delivering a patient-centric, intuitive, and connected experience.
This release supports a wide selection of glucometer devices, enhancing YPrime's eCOA connected device strategy as the Company continues to expand device integrations to support multiple therapeutic areas. The new glucometer functionality addresses the unique needs of diabetes patients, sites, and clinical trial sponsors. Key highlights include: "We are thrilled to introduce this revolutionary glucometer functionality, born out of our commitment to patient-focused innovation," said Mike Hughes, Chief Product Officer of YPrime.
"By listening closely to patients living with diabetes and leveraging our expertise in eCOA, we have created a solution that truly empowers patients and unlocks new possibilities for endocrinology clinical trials and any indication requiring blood glucose logs." YPrime's dedication to patient-centricity was evident throughout the development process of the glucometer functionality. The Company conducted in-depth interviews with patients and received valuable insights about their lived experiences to drive the fea.